Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial
Matthew F Mart,Leanne M Boehm,Amy L Kiehl,Michelle N Gong,Atul Malhotra,Robert L Owens,Babar A Khan,Margaret A Pisani,Gregory A Schmidt,R Duncan Hite,Matthew C Exline,Shannon S Carson,Catherine L Hough,Peter Rock,Ivor S Douglas,Daniel J Feinstein,Robert C Hyzy,William D Schweickert,David L Bowton,Andrew Masica,Onur M Orun,Rameela Raman,Brenda T Pun,Cayce Strength,Mark L Rolfsen,Pratik P Pandharipande,Nathan E Brummel,Christopher G Hughes,Mayur B Patel,Joanna L Stollings,E Wesley Ely,James C Jackson,Timothy D Girard
DOI: https://doi.org/10.1016/s2213-2600(24)00077-8
IF: 102.642
2024-05-03
The Lancet Respiratory Medicine
Abstract:Summary Background Delirium is common during critical illness and is associated with long-term cognitive impairment and disability. Antipsychotics are frequently used to treat delirium, but their effects on long-term outcomes are unknown. We aimed to investigate the effects of antipsychotic treatment of delirious, critically ill patients on long-term cognitive, functional, psychological, and quality-of-life outcomes. Methods This prespecified, long-term follow-up to the randomised, double-blind, placebo-controlled phase 3 MIND-USA Study was conducted in 16 hospitals throughout the USA. Adults (aged ≥18 years) who had been admitted to an intensive care unit with respiratory failure or septic or cardiogenic shock were eligible for inclusion in the study if they had delirium. Participants were randomly assigned—using a computer-generated, permuted-block randomisation scheme with stratification by trial site and age—in a 1:1:1 ratio to receive intravenous placebo, haloperidol, or ziprasidone for up to 14 days. Investigators and participants were masked to treatment group assignment. 3 months and 12 months after randomisation, we assessed survivors' cognitive, functional, psychological, quality-of-life, and employment outcomes using validated telephone-administered tests and questionnaires. This trial was registered with ClinicalTrials.gov , NCT01211522 , and is complete. Findings Between Dec 7, 2011, and Aug 12, 2017, we screened 20 914 individuals, of whom 566 were eligible and consented or had consent provided to participate. Of these 566 patients, 184 were assigned to the placebo group, 192 to the haloperidol group, and 190 to the ziprasidone group. 1-year survival and follow-up rates were similar between groups. Cognitive impairment was common in all three treatment groups, with a third of survivors impaired at both 3-month and 12-month follow-up in all groups. More than half of the surveyed survivors in each group had cognitive or physical limitations (or both) that precluded employment at both 3-month and 12-month follow-up. At both 3 months and 12 months, neither haloperidol (adjusted odds ratio 1·22 [95% CI 0·73–2.04] at 3 months and 1·12 [0·60–2·11] at 12 months) nor ziprasidone (1·07 [0·59–1·96] at 3 months and 0·94 [0·62–1·44] at 12 months) significantly altered cognitive outcomes, as measured by the Telephone Interview for Cognitive Status T score, compared with placebo. We also found no evidence that functional, psychological, quality-of-life, or employment outcomes improved with haloperidol or ziprasidone compared with placebo. Interpretation In delirious, critically ill patients, neither haloperidol nor ziprasidone had a significant effect on cognitive, functional, psychological, or quality-of-life outcomes among survivors. Our findings, along with insufficient evidence of short-term benefit and frequent inappropriate continuation of antipsychotics at hospital discharge, indicate that antipsychotics should not be used routinely to treat delirium in critically ill adults. Funding National Institutes of Health and the US Department of Veterans Affairs.
respiratory system,critical care medicine